Engineered exosome-mimetic nanoparticles improve liver function in aged mice
The synthetic particles deliver microRNAs and proteins to reduce senescence, lower fibrosis, and shift macrophages toward a pro-resolving state.
Biomaterials advances · Zhang L et al. · Paper published 24 Sep 2026
In aged mice, systemic treatment with engineered exosome-mimetic lipid nanoparticles revitalized baseline liver function. Researchers developed the controllable nanotherapeutic to address the manufacturing bottlenecks and batch heterogeneity common to natural mesenchymal stem cell-derived exosomes. The synthetic platform employed a microfluidic procedure to standardize a ten-component core containing three master-regulatory microRNAs and seven functional proteins. In vitro and in vivo evaluations showed the nanoparticles had favorable biosafety, rapid hepatic internalization, and immunological inertness. Mechanistically, the therapy modulated collapsed mitochondrial energy networks, attenuated the senescence-associated secretory phenotype, and reduced age-related fibrotic architectures. The particles also remodeled the liver immune microenvironment, shifting macrophage populations toward a pro-resolving M2-like state and attenuating chronic inflammaging.
Why it matters
Targeting hepatic senescence and inflammaging with standardized synthetic nanoparticles offers a pharmacological strategy to restore function in aged donor organs. This approach could eventually help expand the usable donor pool for liver transplantations.
Caveats
The findings are limited to cell cultures and aged mice. The authors state that further evaluations in donor-graft and transplantation models are required to determine clinical translational potential.
Written from the paper’s abstract, and every claim checked against it before publishing. Read the paper for the full methods and data.
The paper
The application of engineered exosome-mimetic lipid nanoparticles in the hepatic rejuvenation of aged donor livers
Zhang L, Ding R, Zheng D et al.
Biomaterials advances · 24 Sep 2026 · Peer-reviewed
- Relevance
- Core geroscience
- News value
- Notable
- Evidence
- Animals
- Status
- Peer-reviewed
More on Cellular senescence
See allDasatinib and quercetin reduce liver fibrosis in a phase-2 MASH trial
The senolytic combination improved liver fibrosis without disease worsening in nearly half of treated participants while lowering cellular senescence markers.
Nature metabolism · Koning M et al.
A distinct p21-driven macrophage senotype accumulates during aging and liver disease
Researchers identified a p53-p21-Cyclin D2 axis that governs senescent macrophages in mice and human liver cirrhosis and can be cleared with senolytics.
bioRxiv · Torres G et al.
DNA methylation proxies of senescence markers track human disease and mortality
The new blood-based tools estimate senescence gene activity to predict incident diseases, all-cause mortality, and clinical treatment responses.
medRxiv · Simpson DJ et al.
Bispecific T cell engager eliminates senescent cells in mice and nonhuman primates
Monitored by serum transaminase levels, low doses of the drug alleviated age-related pathologies without causing the hepatotoxicity seen at higher doses.
Aging cell · Deng J et al.
A deep learning score for cellular senescence predicts human mortality and disease risk
The proteomic biomarker tracked chronic illness risk in the UK Biobank and shifted following an 18-month multimodal exercise intervention.
Aging cell · Zhao S et al.